Shares of Regenxbio Inc. (NASDAQ:RGNX) saw an uptick in trading volume on Tuesday . 625,553 shares changed hands during mid-day trading, an increase of 144% from the previous session’s volume of 256,573 shares.The stock last traded at $15.96 and had previously closed at $15.15.

Several brokerages have recently weighed in on RGNX. Zacks Investment Research raised shares of Regenxbio from a “hold” rating to a “buy” rating and set a $8.75 price objective on the stock in a research report on Wednesday, July 6th. Chardan Capital reissued a “buy” rating on shares of Regenxbio in a research report on Monday, August 22nd. Finally, Piper Jaffray Cos. reissued a “buy” rating and issued a $33.00 price objective on shares of Regenxbio in a research report on Tuesday, July 5th. One equities research analyst has rated the stock with a hold rating and four have issued a buy rating to the stock. Regenxbio currently has a consensus rating of “Buy” and a consensus price target of $26.75.

The company has a 50-day moving average price of $11.90 and a 200-day moving average price of $10.90. The firm’s market cap is $422.12 million.

This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/20/regenxbio-inc-rgnx-sees-unusually-high-trading-volume.html

Regenxbio (NASDAQ:RGNX) last posted its quarterly earnings data on Tuesday, August 9th. The company reported ($0.55) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.53) by $0.02. Regenxbio had a negative return on equity of 17.89% and a negative net margin of 451.73%. On average, equities research analysts anticipate that Regenxbio Inc. will post ($2.37) EPS for the current year.

A number of institutional investors have recently bought and sold shares of the company. Perceptive Advisors LLC increased its position in Regenxbio by 33.2% in the second quarter. Perceptive Advisors LLC now owns 1,099,213 shares of the company’s stock worth $8,793,000 after buying an additional 273,817 shares in the last quarter. Vivo Capital LLC purchased a new position in Regenxbio during the first quarter worth about $10,697,000. Franklin Resources Inc. increased its position in Regenxbio by 1,004.9% in the second quarter. Franklin Resources Inc. now owns 700,500 shares of the company’s stock worth $5,604,000 after buying an additional 637,100 shares in the last quarter. BlackRock Advisors LLC increased its position in Regenxbio by 27,318.5% in the second quarter. BlackRock Advisors LLC now owns 687,657 shares of the company’s stock worth $5,501,000 after buying an additional 685,149 shares in the last quarter. Finally, Vanguard Group Inc. increased its position in Regenxbio by 116.4% in the second quarter. Vanguard Group Inc. now owns 569,935 shares of the company’s stock worth $4,559,000 after buying an additional 306,596 shares in the last quarter. 68.73% of the stock is currently owned by hedge funds and other institutional investors.

About Regenxbio

REGENXBIO Inc is a biotechnology company. The Company is focused on the development, commercialization and licensing of recombinant adeno-associated virus (AAV) gene therapy. Its AAV gene delivery platform (its NAV Technology Platform) consists of rights to over 100 novel AAV vectors, including AAV7, AAV8, AAV9 and AAVrh10 (NAV Vectors).

5 Day Chart for NASDAQ:RGNX

Receive News & Ratings for Regenxbio Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regenxbio Inc. and related companies with MarketBeat.com's FREE daily email newsletter.